How does PHX's PS Ratio compare to its peers?

PHX is expensive based on its Price-To-Sales Ratio (5.1x) compared to the peer average (2.3x).

How does PHX's PS Ratio compare vs other companies in the AU Software Industry?

PHX is expensive based on its Price-To-Sales Ratio (5.1x) compared to the Australian Software industry average (3.1x).

What is PHX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PHX's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of PHX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PHX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

PharmX Technologies (CHIA:PHX) - Stock Price, News & Analysis

PHX Stock Overview

Operates as a technology and software development company in Australia. More details

PHX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Became profitable this year

Risk Analysis

Does not have a meaningful market cap (A$41M)

Volatile share price over the past 3 months compared to the Australian market

PharmX Technologies Limited Competitors

Xref

ASX:XF1

AU$40.2m

Pointerra

ASX:3DP

AU$34.5m

Adacel Technologies

ASX:ADA

AU$28.2m

Reckon

ASX:RKN

AU$64.0m

Price History & Performance

Summary of all time highs, changes and price drops for PharmX Technologies
Historical stock prices
Current Share Price	AU$0.054
52 Week High	AU$0.061
52 Week Low	AU$0.012
Beta	1.25
11 Month Change	28.57%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-18.18%
5 Year Change	-31.65%
Change since IPO	-50.91%

Recent updates

Shareholder Returns

	PHX	AU Software	AU Market
7D	0%	-3.6%	0.9%
1Y	n/a	80.4%	18.4%

Return vs Industry: Insufficient data to determine how PHX performed against the Australian Software industry.

Return vs Market: Insufficient data to determine how PHX performed against the Australian Market.

Price Volatility

Is PHX's price volatile compared to industry and market?
PHX volatility
PHX Average Weekly Movement	13.5%
Software Industry Average Movement	9.2%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: PHX's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine PHX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1950	n/a	Tom Culver	pharmx.com.au

PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering gateway; PharmX Marketplace, an online sales and marketing platform; and PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limited and changed its name to PharmX Technologies Limited in October 2023.

PharmX Technologies Limited Fundamentals Summary

How do PharmX Technologies's earnings and revenue compare to its market cap?
PHX fundamental statistics
Market cap	AU$41.30m
Earnings (TTM)	AU$95.00k
Revenue (TTM)	AU$8.09m

434.7x

P/E Ratio

5.1x

P/S Ratio

Is PHX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHX income statement (TTM)
Revenue	AU$8.09m
Cost of Revenue	AU$4.13m
Gross Profit	AU$3.96m
Other Expenses	AU$3.87m
Earnings	AU$95.00k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.00016
Gross Margin	48.97%
Net Profit Margin	1.17%
Debt/Equity Ratio	0%

How did PHX perform over the long term?

See historical performance and comparison

PHX Stock Overview

Rewards

Risk Analysis

PharmX Technologies Limited Competitors

ASX:XF1

AU$40.2m

ASX:3DP

AU$34.5m

ASX:ADA

AU$28.2m

ASX:RKN

AU$64.0m

Price History & Performance

Recent News & Updates

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Less than half of directors are independent

Less than half of directors are independent

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

New major risk - Market cap size

Less than half of directors are independent

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

No independent directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

No independent directors

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

Now 20% undervalued

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

No independent directors

Corum Group Limited Launches Pharmxchange Platform

No independent directors

No independent directors

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

No independent directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

No independent directors

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Shareholder Returns

Price Volatility

About the Company

PharmX Technologies Limited Fundamentals Summary

434.7x

5.1x

Earnings & Revenue